Patents by Inventor Barney S. Graham
Barney S. Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10898566Abstract: The present invention relates to a vaccine for Zika virus, the vaccine comprising Zika virus membrane and envelope proteins. More specifically, the vaccine comprises nucleic acid molecules encoding modified Zika virus membrane and/or envelope proteins. When introduced into a cell, the encoded proteins are produced, which results in the production of a virus-like particle capable of eliciting an immune response against Zika virus.Type: GrantFiled: July 28, 2017Date of Patent: January 26, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Barney S. Graham, Theodore C. Pierson, Kimberly A. Dowd, John R. Mascola, Wing-pui Kong, Sung-youl Ko, Eun Sung Yang, Wei Shi, Lingshu Wang, Christina R. Demaso, Rebecca S. Pelc, Adrian Creanga, Julie Ledgerwood, Leda R. Castilho
-
Publication number: 20190374633Abstract: The present invention relates to a vaccine for Zika virus, the vaccine comprising Zika virus membrane and envelope proteins. More specifically, the vaccine comprises nucleic acid molecules encoding modified Zika virus membrane and/or envelope proteins. When introduced into a cell, the encoded proteins are produced, which results in the production of a virus-like particle capable of eliciting an immune response against Zika virus.Type: ApplicationFiled: July 28, 2017Publication date: December 12, 2019Inventors: Barney S. GRAHAM, Theodore C. PIERSON, Kimberly A. DOWD, John R. MASCOLA, Wing-pui KONG, Sung-youl KO, Eun Sung YANG, Wei SHI, Lingshu WANG, Christina R. DEMASO, Rebecca S. PELC, Adrian CREANGA, Julie LEDGERWOOD, Leda R. CASTILHO
-
Publication number: 20190345205Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.Type: ApplicationFiled: November 15, 2017Publication date: November 14, 2019Applicants: GLAXOSMITHKLINE BIOLOGICALS, S.A., The United States of America, as Represented by the Department of Health and Human ServicesInventors: Kimberly DOWD, Barney S. GRAHAM, Sung-Youl KO, Wing-Pui KONG, John MASCOLA, Theodore PIERSON, Mayuri SHARMA, Dong Yu
-
Publication number: 20190314490Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: ApplicationFiled: June 27, 2019Publication date: October 17, 2019Inventors: John R. MASCOLA, Jeffrey C. BOYINGTON, Hadi M. YASSINE, Peter D. KWONG, Barney S. GRAHAM, Masaru KANEKIYO
-
Patent number: 10363301Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: May 27, 2015Date of Patent: July 30, 2019Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
-
Publication number: 20190192651Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: ApplicationFiled: September 1, 2017Publication date: June 27, 2019Inventors: Jeffrey C. BOYINGTON, Barney S. GRAHAM, John R. MASCOLA, Hadi M. YASSINE, Kizzmekia S. CORBETT, Syed M. MOIN, Lingshu WANG, Masaru KANEKIYO
-
Publication number: 20190117760Abstract: The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The methods are useful in preventing or treating a subject having a disease or an infection. In particular examples, the methods are useful for preventing or treating a viral infection.Type: ApplicationFiled: November 2, 2018Publication date: April 25, 2019Inventors: Barney S. Graham, Christopher B. Buck, Jeffrey N. Roberts, Teresa R. Johnson, John Nicewonger, Rhonda Kines, John T. Schiller
-
Publication number: 20180319846Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.Type: ApplicationFiled: July 2, 2018Publication date: November 8, 2018Applicant: The United States of America,as represented by the Secretary,Department of Helath and Human ServicesInventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
-
Patent number: 10017543Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.Type: GrantFiled: March 13, 2014Date of Patent: July 10, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
-
Publication number: 20180021258Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.Type: ApplicationFiled: December 31, 2015Publication date: January 25, 2018Inventors: Barney S. GRAHAM, Masaru KANEKIYO, Hadi M. YASSINE
-
Patent number: 9856313Abstract: The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.Type: GrantFiled: March 17, 2014Date of Patent: January 2, 2018Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Zizheng Zheng, Jason S. McLellan, Man Chen, Min Zhao, Liangmin Huang, Barney S. Graham, Ningshao Xia
-
Publication number: 20170202946Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: ApplicationFiled: May 27, 2015Publication date: July 20, 2017Inventors: John R. MASCOLA, Jeffrey C. BOYINGTON, Hadi M. YASSINE, Peter D. KWONG, Barney S. GRAHAM, Masaru KANEKIYO
-
Publication number: 20160046675Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Applicant: The USA, as represented by the Secretary, Departm- ent of Health and Human ServiceInventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
-
Publication number: 20160031972Abstract: The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.Type: ApplicationFiled: March 17, 2014Publication date: February 4, 2016Applicants: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN UNIVERSITYInventors: Zizheng Zheng, Jason S. McLellan, Man Chen, Min Zhao, Liangmin Huang, Barney S. Graham, Ningshao Xia
-
Patent number: 8772256Abstract: The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.Type: GrantFiled: November 30, 2007Date of Patent: July 8, 2014Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Barney S. Graham, Teresa R. Johnson
-
Publication number: 20120315270Abstract: The present invention provides immunogens that protect against RSV infection. The present invention also provides antibody proteins that protect against RSV infection. Such immunogens and antibody proteins are produced based on three-dimensional models also included in the invention. One model is of a complex between motavizumab and its antibody-binding domain on RSV fusion (F) protein. A second model is of a complex between 10 IF antibody and its antibody-binding domain on RSV F protein. The immunogens disclosed herein have been modified to elicit a humoral response against RSV F protein without eliciting a significant cell-mediated response against RSV. Such immunogens can comprise a scaffold into which RSV contact residues are embedded. The present invention also includes methods that utilize the disclosed three-dimensional models to produce immunogens and antibody proteins of the present invention.Type: ApplicationFiled: October 21, 2010Publication date: December 13, 2012Applicants: UNIVERSITY OF WASHINGTON, SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Jason S. McLellan, Peter D. Kwong, Barney S. Graham, William R. Schief, Joe Jardine, Bruno Correia, Man Chen
-
Publication number: 20110091496Abstract: The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The methods are useful in preventing or treating a subject having a disease or an infection. In particular examples, the methods are useful for preventing or treating a viral infection.Type: ApplicationFiled: January 21, 2009Publication date: April 21, 2011Inventors: Barney S. Graham, Christopher B. Buck, Jeffrey N. Roberts, Teresa R. Johnson, John Nicewonger, Rhonda Kines, John T. Schiller
-
Publication number: 20100247621Abstract: The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.Type: ApplicationFiled: November 30, 2007Publication date: September 30, 2010Applicant: Government of the US, as represented by the Secretary, Department of Health and Human ServicesInventors: Barney S. Graham, Teresa R. Johnson
-
Patent number: 7132453Abstract: The present invention discloses methods and a kit for treating a respiratory syncytial virus infection. The method comprises providing an infection modulator, and administering a therapeutically effective amount of the infection modulator, wherein the respiratory syncytial virus infection is suppressed or precluded. The kit for suppressing a respiratory syncytial virus infection comprises an infection modulator, an applicator, and a set of instructions.Type: GrantFiled: March 14, 2003Date of Patent: November 7, 2006Assignee: Vanderbilt UniversityInventors: Ray Stokes Peebles, Jr., Koichi Hashimoto, Barney S. Graham
-
Publication number: 20030216474Abstract: The present invention discloses methods and a kit for treating a respiratory syncytial virus infection. The method comprises providing an infection modulator, and administering a therapeutically effective amount of the infection modulator, wherein the respiratory syncytial virus infection is suppressed or precluded. The kit for suppressing a respiratory syncytial virus infection comprises an infection modulator, an applicator, and a set of instructions.Type: ApplicationFiled: March 14, 2003Publication date: November 20, 2003Inventors: Ray Stokes Peebles, Koichi Hashimoto, Barney S. Graham